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Abstract
Background: The majority of patients using antihypertensive medications fail to achieve their recommended
target blood pressure. Poor daily adherence with medication regimens and a lack of persistence with
medication use are two of the major reasons for failure to reach target blood pressure. There is no single
intervention to improve adherence with antihypertensives that is consistently effective. Community pharmacists
are in an ideal position to promote adherence to chronic medications. This study aims to test a specific
intervention package that could be integrated into the community pharmacy workflow to enable pharmacists
to improve patient adherence and/or persistence with antihypertensive medications - Hypertension Adherence
Program in Pharmacy (HAPPY).
Methods/Design: The HAPPY trial is a multi-centre prospective randomised controlled trial. Fifty-six pharmacies
have been recruited from three Australian states. To identify potential patients, a software application
(MedeMine CVD) extracted data from a community pharmacy dispensing software system (FRED Dispense®). The
pharmacies have been randomised to either ‘Pharmacist Care Group’ (PCG) or ‘Usual Care Group’ (UCG). To
check for ‘Hawthorne effect’ in the UCG, a third group of patients ‘Hidden Control Group’ (HCG) will be
identified in the UCG pharmacies, which will be made known to the pharmacists at the end of six months. Each
study group requires 182 patients. Data will be collected at baseline, three and six months in the PCG and at
baseline and six months in the UCG. Changes in patient adherence and persistence at the end of six months
will be measured using the self-reported Morisky score, the Tool for Adherence Behaviour Screening and
medication refill data.
Discussion: To our knowledge, this is the first research testing a comprehensive package of evidence-based
interventions that could be integrated into the community pharmacy workflow to enable pharmacists to improve
patient adherence and/or persistence with antihypertensive medications. The unique features of the HAPPY trial
include the use of MedeMine CVD to identify patients who could potentially benefit from the service, control for
the ‘Hawthorne effect’ in the UCG and the offer of the intervention package at the end of six months to patients
in the UCG, a strategy that is expected to improve retention.
Trial Registration: Australian New Zealand Clinical Trial Registry ACTRN12609000705280
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A continuous positive correlation exists between
increasing blood pressure (BP) and mortality rates [1].
The cardiovascular mortality benefit associated with
achieving BP control through medications has been
demonstrated through large-scale clinical trials [2,3].
Unfortunately, the majority of patients on antihyperten-
sive medications fail to achieve their recommended tar-
get BP [4-6]. Poor adherence with medication regimens
and a lack of persistence with medication use are two of
the major reasons for failure to reach target BP [6]. Sev-
eral antihypertensive medication trials have found per-
sistence after one year to be less than 50% [7-9]. On any
day, patients who were still engaged with the drug dos-
ing regimen omitted about 10% of the scheduled doses,
of which 42% were of a single day’s dose and 43% were
part of a sequence of several days [7]. Adherence and
persistence are likely to be much worse in routine clini-
cal practice where, unlike clinical trials, patients’ use of
medications is not closely monitored.
There is no single intervention to improve adherence
with antihypertensives that is consistently effective.
Medication nonadherence is a multi-factorial issue.
Interventions, either individually or in combination, for
improving adherence with antihypertensives that have
some evidence base are: simplifying dosing regimens,
motivational strategies, unit dose packaging, educational
counselling over the telephone, refill reminders, self-
monitoring, and dose-tailoring [10-13]. As medicines
experts in primary care, community pharmacists are in
an ideal position to address adherence and persistence
issues in people with hypertension. In a US study of 200
community-dwelling elderly patients, a 36% absolute
increase in medication adherence followed a compre-
hensive pharmacist intervention with educational and
structural components, which was also associated with
improved cardiovascular outcomes [14]. The educational
component included intensive and frequent counselling
by a pharmacist, while the structural component
involved packaging of medications in blister packs that
contained each patient’s daily medications. Australian
community pharmacists are uniquely positioned in the
healthcare system to undertake a role in cardiovascular
medication management, a role supported by public opi-
nion [15]. However, the pharmacist’sr o l ei na d d r e s s i n g
intentional and unintentional nonadherence to antihy-
pertensive medicines in a sample of patients at risk of
nonadherence remains untested using a randomised
controlled design.
Aim of the research
To test a specific intervention package that could be
integrated into community pharmacy workflow to
enable pharmacists to improve patient adherence and/or
persistence with antihypertensive medications - Hyper-
tension Adherence Program in Pharmacy (HAPPY).
Primary outcome measures
The primary outcomes of the HAPPY trial are changes
in patient adherence and persistence at the end of six
months. These will be measured subjectively using the
self-reported Morisky scale [16] and the Tool for Adher-
ence Behaviour Screening (TABS) [17] and objectively
using the medication refill data (e.g. MedsIndex score
[18]). The Morisky scale assesses both intentional and
unintentional nonadherence and comprises four items.
Responses for each item are scored 0 for ‘yes’ and 1 for
‘no’ (except for the item ‘are you always careful in taking
medicines?’ w h e r et h es c o r ew a sr e v e r s e d )a n da d d e d
together. A total score of zero represents good adher-
ence and a score of one or more represents suboptimal
adherence. The TABS is another self-reported adherence
measure, which was originally developed in Australian
patients using chronic medicines. It has two subscales -
‘adherence’ and ‘nonadherence’ - each comprising four
i t e m st ob ea n s w e r e do na5 - p o i n tL i k e r t - t y p es c a l e
(’never’ -1t o‘always’ -5 ) .T h et o t a ls c o r ef o r‘nonad-
herence’ will be subtracted from that of ‘adherence’;a
differential of ≥15 will be regarded as good adherence
and ≤14 will be regarded as suboptimal adherence. The
TABS measures both intentional and unintentional
deviations from recommended management and has
been shown to have greater incremental validity than
other self-reported adherence measures [17]. The Med-
sIndex gives each patient a score out of 100 for each of
their long-term medications, which is calculated based
on their refill history. Any score less than 100 suggests
suboptimal adherence.
Secondary outcome measures
Secondary outcomes include changes in patients’ BP
control, satisfaction with and willingness to pay for the
service and economic benefits.
Methods/Design
Study Design
The HAPPY trial is a multi-centre prospective rando-
mised controlled trial (RCT).
Study Setting
Community pharmacies included in the trial come from
metropolitan, regional and remote areas in three states
of Australia (Victoria, Western Australia and Tasmania),
proportionally stratified according to Pharmacy Access/
Remoteness Index of Australia (PhARIA) [19] categories.
(PhARIA provides a comprehensive, standardised
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ness of pharmacies throughout Australia, for use in the
determination of rural and remote pharmacy allowances.
The concept of remoteness was based on the road dis-
tance people have to travel to reach a range of services.)
The pharmacies are located in a range of physical loca-
tions such as shopping strips, shopping malls, within
medical centres and stand alone.
Pharmacy Eligibility Criteria
Pharmacies that met all the following criteria were eligi-
ble to participate in the HAPPY trial:
￿ use the pharmacy dispensing program ‘FRED
Dispense®’;
￿ agree to install a software application (MedeMine
CVD) to identify patients who are using or have
used antihypertensive medicines in the previous six
months;
￿ have at least 40 patients who are currently using or
have used antihypertensive medicines in the previous
six months;
￿ have a private counselling area within the phar-
macy where one-on-one consultation with a patient
will be shielded from the public eye and ear;
￿ willingness and ability to attend project training
either face-to-face or online;
￿ have time within the working week to allocate
about one uninterrupted hour per patient to collect
the baseline data; and
￿ able to follow-up participants for at least six
months from baseline.
Recruitment of pharmacies
Contact information for pharmacies was obtained from
the telephone directory/Internet. Pharmacies in each of
the PhARIA categories in each state were contacted by
telephone and informed about the project. An explana-
tory statement and consent form was sent to all eligible
pharmacies, if the pharmacist expressed interest. Upon
receipt of the signed consent form, pharmacies were for-
mally included in the study.
Cluster randomisation
In each state, pharmacies were randomised to either
Pharmacist Care Group (PCG) or Usual Care Group
(UCG) according to the PhARIA. Randomisation was
carried out at the pharmacy level to avoid the contami-
nation likely to result from the same pharmacy recruit-
ing and following up both intervention and control
group patients. Randomisation was carried out at a cen-
tral location using the sealed opaque envelope techni-
que. To check for any ‘Hawthorne effect’ [20,21] in the
U C Gd u et ot h ee f f e c to fd a t ac o l l e c t i o n ,at h i r dg r o u p
of patients (Hidden Control Group - HCG) who are tak-
ing or have taken antihypertensives in the previous six
months (but not included as participants in the UCG)
will also be identified.
Pharmacist Care Group (PCG)
The PCG participants receive a package of interventions
from the pharmacist for enhancing their antihyperten-
sive medication adherence, which includes:
￿ a home BP monitor (Omron®T9IT) with the capa-
city to store and download BP readings to be used
for discussion at three- and six-month follow-ups;
￿ training by the pharmacist on self-monitoring of
BP;
￿ motivational interviewing and education by the
pharmacist to help patients improve their medica-
tion adherence and achieve target BP;
￿ pharmacist-initiated home medicines review
(HMR), dose administration aid (DAA) and/or
patient medication profile (PMP), where necessary;
￿ medication use review (MUR) to identify and
resolve possible medication-related hypertension (e.
g. due to non-steroidal anti-inflammatory drugs,
cold preparations, complementary medicines, etc.);
￿ referral to a GP when needed (e.g. very high blood
pressure); and
￿ refill reminders (by either SMS, telephone or mail)
from their pharmacist at a chosen number of days
before their antihypertensive medication dispensing
is due.
HMRs http://www.medicareaustralia.gov.au/provider/
pbs/fourth-agreement/hmr.jsp are designed to assist
consumers living at home to maximise the benefits of
their medication regimen and prevent medication-
related problems. The review involves the consumer’s
general practitioner (GP) and preferred community
pharmacy, and in some cases other relevant members of
the healthcare team. The GP refers the consumer to the
community pharmacy and an accredited pharmacist vis-
its the consumer at home, reviews their medication regi-
men, and provides the GP with a report. The GP and
consumer then agree on a medication management plan.
A DAA http://www.health.gov.au/internet/main/pub-
lishing.nsf/Content/ppsac-qa-daa is a device developed
to assist patients in better managing their medicines by
arranging their medicines into individual doses accord-
ing to the prescribed dose schedule throughout the day.
T h ea i mo ft h eD A AP r o g r a mi st or e d u c em e d i c a t i o n -
related hospitalisation and adverse events through
improving medication management and adherence for
people in the community.
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lishing.nsf/Content/ppsac-qa-pmp is a comprehensive
written summary of all regular medicines taken by a
patient that assists them in understanding and managing
their medicines by informing them how, when and why
to take their medicines. The aim of the PMP Program is
to reduce the risk of medication-related adverse events
by assisting people to understand and manage their
medications, including prescription, over-the-counter
and complementary medicines.
A MUR http://www.psnc.org.uk/pages/murs_the_ba-
sics.html usually takes place in the pharmacy and it
involves the pharmacist checking the patient’s medica-
tion, making sure that the patient knows how and why
they should be taking their medication, as well as iden-
tifying any problems. It provides the patient with an
o p p o r t u n i t yt oa s kq u e s t i o n sa n dt h ep h a r m a c i s ta n
opportunity to improve the patient’s medication under-
standing and adherence, as well as being able to high-
light problems and provide appropriate solutions.
Usual Care Group (UCG)
UCG pharmacists will continue to offer routine care to
their patients.
Training for Pharmacists
Training was organised for all participating pharmacists
in two modes, face-to-face and online. Materials and
resources were made available as hard copy, online and
on CDs, to provide flexible learning opportunities.
Training comprised two phases:
Phase I
Phase I training was delivered to all participating phar-
macists and included the project overview, patient
recruitment including the use of MedeMine CVD soft-
ware to identify patients using antihypertensive medica-
tions, calculation of MedsIndex score, use of BP
monitors and collection of baseline data.
Phase II
The second phase focused on the importance of medica-
tion adherence in achieving optimal BP control, a clini-
cal update on hypertension management, motivational
interviewing, review of BP monitoring by patients,
downloading home BP recordings, charting BP against
adherence, and identification and resolution of medica-
tion-related hypertension by MUR.
Pharmacists in the PCG were offered Phase II training
before baseline data collection. The UCG pharmacists
will receive Phase II training after the six-month follow-
up, so that control patients can be offered the interven-
tions tested in the PCG after the study. This will
encourage recruitment of pharmacists to the UCG and
improve retention of patients in the UCG.
Sample size
Australian, European and North American studies have
estimated that around 50% of patients initiating an anti-
hypertensive medication discontinue their medication
(become nonpersistent) within twelve months [22]. To
demonstrate a 15% difference in adherence between the
control and intervention groups at six months (e.g. 50%
in the UCG versus 65% in the PCG) with 80% power
and a two-sided p-value of 0.05, 182 patients are
required per study group. To allow for potential drop-
outs (approximately 25% over six months) 225 patients
need to be recruited per group; i.e. a total of 450
patients at baseline.
Recruitment of patient participants
A software application, MedeMine CVD, has been
installed on the dispensing computer of participating
pharmacies. MedeMine CVD extracts data from the
market leading pharmacy dispensing software system in
Australia (FRED Dispense®) and identifies patients who
are using or have used antihypertensive medicines in the
previous six months. The purpose of MedeMine CVD is
to:
1. preferentially identify patients who last had their
antihypertensive medications dispensed more than 59
days previously and those with suboptimal refill
adherence;
2. generate personalised “Expression of Interest” (EOI)
forms to mail to potential patient participants. Once the
completed EOI has been received by the pharmacist and
eligibility is confirmed, the information is recorded in
MedeMine CVD;
3. generate the participant explanatory statement and
consent form, as well as a letter and fax-back form to
be sent to the participant’sG Pt oc o n f i r md i a g n o s i so f
primary hypertension and advise of the participant’st a r -
get BP;
4. manage participant appointments by pharmacists;
5. create a unique identification number for each par-
ticipant, which is printed on all study documents (e.g.
data collection forms and letters); and
6. send SMS reminders or prompt the pharmacist to
telephone or send mail reminders, to participants who
have requested this part of the service, when their sup-
plies are dwindling.
An invitation letter (EOI) with a short questionnaire
(seeking information about the patient’s BP, interest in
participation, nominated GP, including contact details
and consent to contact the GP, and patient telephone
contact details) and a reply-paid envelope were sent to
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completed questionnaire to the pharmacy and indicate
their interest in participating. Once the EOI is received,
the pharmacist will contact the patient to further assess
their eligibility and arrange a mutually convenient time
to visit the pharmacy to enrol in the study. If eligibility
is confirmed, the consent form would then be signed.
The pharmacist will also contact the patient’s GP. At no
point are patients’ identities made known to the
researchers.
Inclusion criteria
￿ using or having used in the last six months at least
one antihypertensive medication belonging to the
four most common classes of antihypertensives in
Australia - angiotensin converting enzyme inhibitors
angiotensin-II receptor antagonists, calcium channel
blockers, beta blockers - http://www.aihw.gov.au/
publications/cvd/mfchatua/mfchatua.pdf or fixed
combinations of antihypertensive medications
belonging to the above classes with other antihyper-
tensives (e.g. diuretics);
￿ a diagnosis of primary hypertension;
￿ 18 years and above; and
￿ available for follow-up for at least six months from
baseline.
Exclusion criteria
￿ participation in other adherence promotion
programs;
￿ having had a pharmacist-conducted HMR service
in the last 12 months;
￿ unable to communicate in English; and
￿ does not self-administer antihypertensive
medicines.
Each pharmacist was asked to recruit 7-10 patients
from their pharmacy.
Data collection
Baseline visit
During the baseline visit to the pharmacy, the pharma-
cist will measure the patient’s BP using a digital BP
monitor (average of two readings as per WHO MON-
ICA [23] and EHRM [24] protocols - if these differ by
more than 5 mmHg, a third reading will be taken and
the average of the two closest readings will be recorded).
Each pharmacy has been provided with a BP monitor.
The MedsIndex score will be calculated for each antihy-
pertensive medicine the patient uses. Adherence will be
measured using self-report tools - the Morisky scale and
the TABS. The Beliefs and Behaviour Questionnaire [17]
will be used to assess patient experiences, attitudes and
beliefs regarding their health and treatment and the 8-
item short Assessment of Quality of Life (AQoL) [25]
will be used to measure health-related quality of life.
The pharmacist will also collect information on the
patient’s medications and their understanding of and
ability to use these medications. The PCG will also
receive the intervention described earlier.
Three-month visit
Pharmacist Care Group (PCG) Only
During the patient’s visit to the pharmacy at three
months, the pharmacist will administer the Morisky
scale and TABS. The pharmacist will also:
￿ download the patient’s home BP measurements for
review and discussion with the patient;
￿ measure patient’s BP (as described above);
￿ document any adherence issues and actions taken;
and
￿ refer patient to their GP, if needed (e.g. persistent
uncontrolled BP even after improvement in
adherence).
Six-month visit (Final project visit)
Measures performed at baseline will be repeated for
both UCG and PCG patients at their six-month visit to
the pharmacy.
Usual Care Group (UCG) Only
Following final measurements, each UCG participant
will receive the same package of interventions offered to
the PCG at baseline. UCG participants will receive fol-
low-up pharmacy services two months after the ‘Final
project visit’. The pharmacist will:
￿ measure patient’s BP (as described above);
￿ review patient’s home BP recordings;
￿ review patient’s BP measurement techniques;
￿ discuss adherence issues; and
￿ refer when needed (e.g. persistent uncontrolled
BP).
Data analysis
Participant characteristics in the UCG and PCG will be
compared at baseline. Paired t-tests and/or Wilcoxon
Signed Rank test will be used to compare changes in
total scores on the Morisky scale, TABS and MedsIndex
between the PCG and the UCG at baseline and six
months. MedsIndex scores will be compared using
paired t-tests and/or Wilcoxon Signed Rank test in the
UCG and the HCG at six months.
Baseline data will be used to identify factors associated
with suboptimal adherence in the whole study population.
Significant factors in univariate analysis (chi-square,
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tested in multivariate analysis (linear regression) to identify
independent predictors of nonadherence/nonpersistence
in the study population. To adjust for cluster randomisa-
tion, a pharmacy variable will also be included in the mul-
tivariate models.
An economic evaluation will also be carried out and
will be reported elsewhere.
Ethics
This project has been approved by the Human Research
Ethics Committees of Monash University, Curtin Uni-
versity and The University of Melbourne, and the
Human Research Ethics Network of Tasmania. All phar-
macists and patient participants (in the UCG and PCG)
provided written informed consent at the time of
enrolment.
Approval to access dispensing data for the HCG was
given on the basis that pharmacists have routine access
to this data about their patients via the dispensing pro-
gram and would use it in normal practice to routinely
check their patient’s history for actual or potential medi-
cation-related problems. The researchers will have
access only to deidentified patient data.
Study timeline
Trial start: June 2009
Baseline data collection: June-August 2009
Three-month data collection: October-November 2009
Six-month data collection: December 2009-January
2010
Data analysis: February 2010
Discussion
To our knowledge, HAPPY trial is the first RCT testing a
comprehensive package of evidence-based interventions
able to be integrated into the community pharmacy work-
flow, to enable pharmacists to improve patient adherence
and/or persistence with antihypertensive medications.
HAPPY trial is unique because we have taken into consid-
eration the ‘Hawthorne effect’ in the UCG by having a
third group of patients (HCG) who are taking or have
taken antihypertensives in the previous six months but not
included in the UCG. In addition, UCG pharmacists and
their patient participants will not be disadvantaged as,
after the study period is completed, they will be offered
the intervention package tested in the PCG, a strategy that
is expected to enhance participant retention.
Trial registration
Australian New Zealand Clinical Trial Registry
ACTRN12609000705280
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